Harvard Pilgrim Health Care Home
  HPHConnect
 
  Learn more.
  Sign up for HPHConnect.
Medical Management
E-Transactions
HPHConnect
Pharmacy
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Newsroom
Office Support
Products
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
 
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2016

P&T Committee Updates


At the March 7th, 2016 meeting, the Harvard Pilgrim Pharmacy & Therapeutics Committee reviewed five medications and decided the following.

P&T Committee Review and Decisions

Name

Description and Indication

Decision

Brintellix (vortioxetine)  

Brintellix is an antidepressant used to treat major depressive disorder in adults. 

  • Premium formulary: Continued coverage at non-preferred brand tiers with step therapy requirements
  • Value formulary: Added to non-preferred brand tier with step therapy requirements
  • Medicare Advantage Formulary: Continued coverage at non-preferred brand tier

Mirvaso (brimonidine)   

Mirvaso is an alpha adrenergic agonist indicated for the treatment persistent facial redness of rosacea in adults.

  • Premium formulary: Continued coverage at non-preferred brand tiers
  • Value formulary: Remains non-covered
  • Medicare Advantage formulary: Continued coverage at Tier 4

Rexulti (brexpiprazole)  

Rexulti (brexpiprazole) Rexulti is an antipsychotic used in addition to an antidepressant for the treatment of major depressive disorder.  It is also indicated for the treatment of schizophrenia.

  • Premium formulary: Continued coverage at non-preferred brand tiers with prior authorization
  • Value formulary: Remains non-covered 
  • Medicare Advantage formulary: Continued coverage at Tier 5 (Specialty Tier)

Rytary (carbidopa and levodopa capsules) 

Rytary is a combination of carbidopa and levodopa indicated for the treatment of Parkinson’s disease, post-encephalitic parkinsonism, and Parkinson’s disease resulting from carbon monoxide or manganese poisoning. 

  • Premium formulary: Coverage at non-preferred brand tiers with added prior authorization
  • Value formulary:  Remains non-covered
  • Medicare Advantage Formulary: Remains non-covered

Soolantra (ivermectin) 

Soolantra cream is indicated for the treatment of inflammatory lesions of rosacea.

  • Premium formulary: Continued coverage at non-preferred brand tiers
  • Value formulary:  Remains non-covered
  • Medicare Advantage Formulary: Remains non-covered

Email this article to a colleague   


Network Matters Archives

Download printer-friendly version

HPHCURRENT EVENTS

Important Referral Reminders for PCPs

New Medicare Advantage FDR Compliance Program Website Available

CLINICIAN CORNER

Vaccine Policy: Updates Regarding State-Supplied Vaccines

Clinical Policy and Prior Authorization Updates

Upcoming Clinical Reviews: Give Us Your Feedback

Updates to Harvard Pilgrim’s Nexium Coverage

Diabetes Outreach Program for Medicare Advantage Members

Harvard Pilgrim’s Commitment to Health Equity

P&T Committee Updates

Specialty Pharmacy Program Updates

Reminder Regarding Annual Well Visits

OFFICE ASSISTANT

Benefit from the Convenience of Electronic Funds Transfer

Reminder: Use of Non-Participating Ambulance Providers

PUBLICATION INFORMATION

Eric H. Schultz,
President and Chief Executive Officer

Robert Farias,
Vice President, Network Services

Annmarie Dadoly,
Editor

Joseph O'Riordan,
Writer

Kristin Edmonston,
Production Coordinator